Key Takeaways
- Alzheimer’s Drug Discovery Foundation CFO Karen Harris talked to Scrip about the investment outlook in Alzheimer’s disease nearly four years after the launch of the first anti-amyloid drug.
- Pharma interest is regaining momentum after a lull, she said, confident that recent investment in CNS disorders will bode positively for Alzheimer’s disease as well.
- ADDF has about $40m to invest in therapeutics this year, money it plans to direct toward drugs that address the biology of aging and combination therapies.
Despite notable advancements in Alzheimer’s disease treatment during the last five years, the therapeutic area remains a complex and uncertain area for drug developers
The high unmet need in Alzheimer’s and the large patient population keeps pharma interested in the space, however, and after digesting the commercially underwhelming initial launches of Eisai/Biogen’s Leqembi (lecanemab) and Lilly’s Kisunla (donanemab), the big question is where industry will focus its investments next in the heterogeneous disease, where
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
